This provides further treatment options for rhabdomyosarcoma by using EZH2 inhibitors as adjuvant therapy, thus with a likely possibility of increasing the effectiveness of current conventional treatment (97). This evidence concerns the gene EZH2 and rhabdomyosarcoma.